A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Condition:   Relapsed or Refractory Multiple Myeloma Interventions:   Drug: Cevostamab;   Drug: Elranatamab;   Drug: Tocilizumab Sponsor:   Genentech, Inc. Not yet recruiting

Source: ClinicalTrials.gov - July 3, 2023 Category: Research Source Type: clinical trials